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ABSTRACT: Inhalable theophylline particles with various amounts of 
mannitol were prepared by combining wet milling in isopropanol followed 
by spray drying. The effect of mannitol as a co-milling agent on the 
micromeritic properties, solid state and aerosol performance of the 
engineered particles was investigated. Crystal morphology modelling and 
geometric lattice matching calculations were employed to gain insight into 
the intermolecular interaction that may influence the mechanical 
properties of theophylline and mannitol. The addition of mannitol 
facilitated the size reduction of the needle-like crystals of theophylline and 
also their assembly in microcomposites by forming a porous structure of 
mannitol nanocrystals wherein theophylline particles are embedded. The 
microcomposites were found to be in the same crystalline state as the 
starting material(s) ensuring their long-term physical stability on storage. 
Incorporation of mannitol resulted in microcomposite particles with 
smaller size, more spherical shape and increased porosity. The aerosol 
performance of the microcomposites was markedly enhanced compared to 
the spray-dried suspension of theophylline wet milled without mannitol. 
Overall, wet co-milling with mannitol in an organic solvent followed by 
spray drying may be used as a formulation approach for producing 
respirable particles of water-soluble drugs or drugs that are prone to 
crystal transformation in an aqueous environment (i.e. formation of 
hydrates).  
Keywords: Co-milling, dry powders for inhalation, mannitol, spray 
drying, theophylline 
 
1. INTRODUCTION 
The classical formulation approach for drug delivery to the lungs using dry 
powder inhalers (DPIs) is micronising the active pharmaceutical ingredient 
(API) and then mixing with a suitable coarse carrier (e.g. lactose, 
mannitol). Micronisation (e.g. by ball or air-jet milling for particle size 
reduction) may generate amorphous domains on the drug particle surface. 
The amorphous state tends to revert back to a lower energy and more 
stable crystalline state upon storage, which may adversely influence the 
product performance as it affects critical particle properties such as the 
morphology, particle size distribution, dissolution and aerosolisation 
(Brodka-Pfeiffer et al., 2003; Chow et al., 2007). Therefore, preparation 
of nanosuspensions by a wet size reduction technique (e.g. wet milling, 
high pressure homogenisation, antisolvent precipitation) followed by 
solidification, using spray drying, has been suggested as a preparation 
platform for inhalable micron-sized composites of nanocrystals with 
enhanced dissolution and aerosolisation efficiency (Bosch et al., 1999; 
Malamatari et al., 2015; Pilcer et al., 2009; Yamasaki et al., 2011). 
The majority of such reported applications  (nanos-in-micros particle 
engineering approach) has focused on poorly water-soluble drugs and 
thus the size reduction step can take place in aqueous media where the 
drug is dispersed but not dissolved (Duret et al., 2012; Pomázi et al., 
2013). However, some drugs used for the treatment of respiratory 
diseases are moderately or very water-soluble, such as salbutamol sulfate 
(albuterol sulfate) and terbutaline sulfate, or are prone to hydrate 
formation, e.g. nedocromil sodium. Therefore, water cannot be used as 
the wet milling medium, in the preparation of nanosuspensions, nor as the 
solvent during the spray-drying step as for poorly water-soluble drugs. 
Instead, an appropriate organic solvent has to be selected, in which the 
drug exhibits a solubility lower than 10 mg ml-1 and ideally lower than 5 
mg ml-1 (Hong and Oort, 2011), to eliminate the possibility of crystallinity 
changes  (e.g. amorphisation) during milling and spray drying. 
Theophylline has been chosen as the model compound in this study as it 
has a long history of use within respiratory medicine, and its solid-state 
properties have been extensively investigated. More specifically, 
anhydrous theophylline is a challenging molecule with respect to wet 
milling and spray drying due to the following physicochemical properties:  
(i) It is a moderately water-soluble drug (7.36 mg ml-1, at 25 o 
C, Yalkowsky and He, 2003). 
(ii) Its needle-like crystal shape morphology can affect its 
fracture/breakage behavior, as reported for other organic 
crystalline materials.  
(iii) It is prone to process-induced solid-state transformations as 
it exists in four polymorphic forms (forms I-IV) along with a 
monohydrate form (Fucke et al., 2012). Form II is the stable 
polymorph at room temperature while the monohydrate is 
the stable form in water and at high relative humidity 
environment.  
From a pharmacological point of view, theophylline is a widely available 
and inexpensive methylxanthine that has been used in the treatment of 
airway diseases such as asthma and chronic obstructive pulmonary 
disorder (COPD) for more than 90 years (Barnes, 2013).  
The use of theophylline has been limited by its narrow therapeutic index 
(TI) and marked inter-subject variability of its clearance. A therapeutic 
plasma concentration of 10 - 20 mg L-1 is required for theophylline to 
achieve bronchodilation comparable with β2-agonists, while side effects 
(e.g. nausea, vomiting, heartburn, diarrhea) become an issue at 
concentrations above 20 mg L-1 (Barnes, 2013). Due to its narrow TI, it is 
administered as oral sustained-release (SR) preparations.  
There is increasing evidence that theophylline at low doses (plasma 
concentrations < 7 mg L-1) exhibits immunomodulatory properties in the 
pathophysiology of both asthma and COPD (Barnes, 2013). Moreover, it 
has been reported that theophylline has the potential to enhance the anti-
inflammatory effect of corticosteroids and reverse steroid resistance that 
is common in COPD patients (Hirano et al., 2006; Tilley, 2011). These 
observations may lead to the reevaluation of this old drug in the future, 
once clinical trials of low-dose theophylline therapy are completed 
(Barnes, 2008; 2003).  
Theophylline applied intratracheally as a dry powder formulation to the 
airways of anaesthetised guinea pigs exhibited smooth muscle relaxant 
and anti-inflammatory properties at very low doses that would be 
predicted to have no systemic toxicity (Raeburn and Woodman, 1994). 
Thus, developing inhalable formulations for theophylline may offer 
advantages over oral administration for the treatment of inflammation in 
asthma and COPD, enhancing the local efficacy of the drug while 
minimising systemic side effects (Raeburn and Woodman, 1994; Zhu et 
al., 2015a).  
There are few published studies on engineering inhalable theophylline 
particles. A low-dose pressurised metered-dose inhaler (pMDI) 
formulation of theophylline (Zhu et al., 2015a) and formulations for dry 
powder inhalers (polymeric composite particles, microspheres, cocrystals 
and nanosized rods agglomerates) have been  produced and characterised 
(Alhalaweh et al., 2013; Kadota et al., 2015; Momeni and Mohammadi, 
2009; Salem et al., 2011; Zhang et al., 2009; Zhu et al., 2015b). Blends 
of theophylline microparticles (63-90 μm) with inhalable budesonide and 
terbutaline particles (< 5 μm) were proposed as a formulation approach 
for concurrent oral and pulmonary drug delivery with theophylline acting 
as a carrier (Salama et al., 2014).  
DPIs have many advantages (inherent stability of dry powders, 
administration of high doses, short delivery times, the absence of 
propellants and breath-actuation) compared to other inhalation devices, 
namely pMDIs and nebulisers (Atkins, 2005).  
The aim of the present work is to produce inhalable dry powder 
formulations of theophylline, by coupling wet bead milling in an organic 
solvent followed by spray drying of the milled suspension. The effect of 
mannitol addition during the wet milling of theophylline on the 
micromeritic, solid state and aerosol performance of the produced spray-
dried particles was investigated. The experimental data of this study were 
complemented with a computational study of the interaction between 
theophylline and mannitol (i.e. crystal morphology modelling and lattice 
matching calculations) in order to elucidate the role of mannitol as a co-
milling agent.  
2. MATERIALS AND METHODS  
2.1 Materials 
Theophylline (THEO), 3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione (LKT 
Laboratories, USA), was used as the drug under investigation. D-mannitol 
(MAN, Pearlitol 160C®, Roquette Freres, France) was used as co-milling 
agent and matrix former of the microcomposites. Isopropanol (IPA, 
Thermo Scientific, UK) was used as the milling medium for the 
preparation of suspensions. Methanol and water both from Fisher 
Scientific UK, and trifluoroacetic acid (TFA, Sigma-Aldrich Co., USA) were 
used for the HPLC analysis. All the solvents used were of analytical grade. 
2.2 Methods 
2.2.1 Preparation of suspensions 
Suspensions were prepared by wet bead milling using a laboratory 
planetary mill (Pulverisette 5, Fritsch Co., Germany). 1.0 g of solids 
(THEO and MAN), 10 g of milling beads (0.5 mm diameter aluminum 
borosilicate glass grinding beads, Gerhardt Ltd, UK) were weighed into a 
glass vial of 14 ml capacity and suspended in 10 ml IPA, as the dispersing 
medium. The total concentration of solids (THEO and MAN) in suspension 
was kept constant (5% w/v) and different THEO to MAN mass ratios (i.e. 
25:75, 50:50 and 75:25) were employed (Table 1). The vials were placed 
into a stainless steel milling pot with a maximum loading capacity of 8 
pots. Rotation speed (300 rpm) and milling duration (6 cycles of altered 
bowl rotation direction) were selected based on preliminary experiments. 
Each milling cycle comprised 60 min rotation followed by 20 min pause to 
cool down the milling vessels and to prevent overheating of the 
instrument’s rotors. The suspensions were left to cool to room 
temperature and collected by withdrawal with a pipette to separate from 
the milling beads.  
2.2.2 Preparation of spray-dried microcomposite particles  
The obtained suspensions were diluted 1:2 with IPA, before spray-drying, 
to obtain suspensions with an overall solid concentration 5% w/v in IPA. 
Spray drying was performed with a Gea Niro Spray Dryer SD MicroTM (Gea 
Process Engineering, Denmark) operated with nitrogen as the drying gas. 
Inlet temperature of 80 ± 3 o C was selected, and atomizer gas flow and 
chamber inlet flow were set at 2.5 and 25 kg h-1, respectively. The nozzle 
pressure was set at 1.5 bar and the bag filter pressure at 2.1 bar. The 
outlet temperature control was set at 20%, resulting in outlet 
temperature of 60 ± 5 o C.  
2.2.3 Characterisation of spray-dried microcomposite particles 
The spray-dried powders were characterised for: particle surface 
morphology and shape by scanning electron microscopy (SEM) and image 
analysis of the SEM images; particle size distribution (PSD) by laser 
diffractometry; specific surface area by Brunauer-Emmett-Teller (BET) 
method; solid state by X-ray powder diffraction (XRPD), Fourier transform 
infrared spectroscopy (FT-IR) and differential scanning calorimetry (DSC); 
drug loading by HPLC analysis of theophylline content and in vitro aerosol 
performance using the next generation impactor (NGI). 
2.2.3.1 Scanning electron microscopy (SEM) 
Samples were placed on a double-side electroconductive adhesive tape, 
which was fixed on an aluminum stub then coated with gold under argon 
atmosphere to a thickness of 10 nm (Quorum model 150). SEM 
micrographs were taken using a FEI Quanta 200 FEG ESEM (Netherlands), 
at 5.00 kV.  
2.2.3.2 Image Analysis 
SEM images were processed with the open source image processing 
software FIJI/Image J (Schindelin et al., 2012) to determine the number-
based aspect ratio of the particles. The major and minor axis (i.e. primary 
and secondary axis of the best fitting ellipse) of a minimum of 100 
particles was measured for each spray-dried powder and for the starting 
materials, and the aspect ratio was calculated as the ratio of the minor to 
the major axis. 
2.2.3.3 Laser diffraction size analysis 
HELOS/ BR laser diffractometer (Sympatec GmbH, Germany) fitted with 
the micro-dosing unit ASPIROS and combined with the dry disperser 
RODOS was employed. Samples were placed in the feeder and pressurised 
air of 4 bar was used to disperse them in the measurement chamber while 
the feeding velocity was constant at 50 mm sec-1. An R2 lens detector 
(0.25- 87.5 μm) and the particle size distribution (PSD) analysis software 
Windox 5 were used.  
The particle size distribution of the starting materials was measured with 
Malvern Mastersizer 3000 equipped with a dry sampling system (Aero S, 
Malvern Instruments, UK), as the particle size range covered by this laser 
diffractometer is 0.1-3500 μm. The standard operating conditions used 
were: refractive index: 1.52, vibration feed rate: 25%, measurement 
time: 5 s, dispersive air pressure: 4 bar.  
In all the cases, particle size parameters corresponding to the 10th, 50th, 
90th percentile of particles (D10%, D50%, D90%) were recorded.  
2.2.3.4 Specific surface area and porosity 
The specific surface area was measured using the nitrogen adsorption 
Brunauer-Emmett-Teller (BET) method with a Quantachrome Nova 4200e 
multi-station gas sorption surface area analyser (Quantachrome Ltd, UK) 
Approximately 0.1 g of each powder was placed in each sample cell, and 
the outgassing process was conducted at 105 o C over 2 h. The total pore 
volume and the average pore radius were calculated following the t-plot 
method.  
2.2.3.5 X-ray powder diffractometry (XRPD) 
XRPD patterns were obtained with a bench-top diffractometer (Rigaku 
Miniflex 600, Japan) to assess crystallinity. Cu Kα radiation at 15 mA and 
40 kV with a step of 0.02 deg and a speed of 5 deg min-1 was used, 
covering a 2 theta of 3-40 o. Miniflex Guidance was the analysis software.  
 
2.2.3.6 Fourier transform infrared spectroscopy (FT-IR)  
Spectra of the starting materials, their physical mixtures and the 
microcomposites were recorded using a PerkinElmer Spectrum100 FT-IR 
spectrometer equipped with the attenuated total reflection (ATR) sampling 
accessory. Samples were scanned at room temperature, at the 
transmission mode, over a wavenumber range of 4000-650 cm-1, 16 
accumulations and 1 cm-1 resolution. Before each measurement, a 
background spectrum of air was acquired under the same instrumental 
conditions. The acquired spectra were processed using the PerkinElmer 
Spectrum Express software (PerkinElmer, Inc., USA). 
2.2.3.7 Differential scanning calorimetry (DSC) 
DSC was performed using a TA DSC Q200 previously calibrated with 
indium. Weighed powder samples (1-3 mg) were sealed into crimped 
standard aluminum pans (TA) and heated under nitrogen flow (50 ml min-
1) from 25 o C to 30 o C above their melting point, at a heating rate of 10 o 
C min-1.  
2.2.3.8 Drug loading 
5 mg of each spray-dried formulation were dissolved in 25 ml water and 
theophylline concentration was determined using an HPLC system (Agilent 
1100 Series, Agilent Technologies, Germany) following the method 
described by Alhalaweh et al. (2013). The correlation coefficient of the 
calibration curve was R2: 0.9997 for a concentration range of 5-400 μg 
ml-1, indicating acceptable linearity. 
 
2.2.3.9 In vitro aerosol performance  
Deposition profiles were determined with Ph. Eur. Apparatus E (Next 
Generation Impactor, NGI, Copley Instruments Ltd, UK) fitted with a 
stainless steel 90O induction port (IP) and a pre-separator (PS) operated 
as specified in European Pharmacopoeia (Ph. Eur. 8th edition, monograph 
2.9.18) and connected to a high-capacity vacuum pump (Model HCP5, 
Copley Instruments Ltd, UK). Prior to use, the impaction cups in each of 
the seven stages were coated with 1% w/v silicone oil solution in hexane, 
and allowed to dry for 1 h, in order to minimise ‘particle bounce’ and 
entrainment of particles between the stages. The final stage of the 
impactor, known as micro-orifice collector (MOC), was fitted with a 
fiberglass filter (nylon 0.45 μm, Millipore, UK). The flow rate was 
measured using a flow meter (Flow Meter Model DFM 2000, Copley 
Instruments Ltd, UK) prior to each run, to ensure that a flow of 60 L min-1 
was achieved. Gelatin capsules (size 3) were filled with accurately weight 
amounts of product corresponding to about 10 mg of THEO. Following 
filling, capsules were stored in a desiccator over silica gel for 24h prior to 
performing the deposition study. Storage for 24h allowed relaxation of 
any electrical charge without influencing the brittleness of the capsules as 
their water content in preliminary studies was found to be inside the 
normal moisture specification limits (13-16% for gelatin). The inhaler 
device (Cyclohaler®) was connected to the impactor via an airtight rubber 
mouthpiece adaptor and tested at 60 L min-1 for an actuation time of 4 s.  
The capsules were discharged into the NGI, and after dispersion the 
powder deposited on the capsules, mouthpiece, inhaler and each NGI part 
was collected by exhaustively washing with water (HPLC grade) 
transferred into volumetric flasks and assayed. The HPLC conditions for 
the assay were identical to those for drug content determination. To 
characterise the aerosol performance the following parameters were 
determined: the emitted fraction (EF %) was calculated as the ratio of the 
drug mass depositing in the mouthpiece, induction port, pre-separator, 
and impactor stages (1 to MOC) to the cumulative mass of drug collected 
following actuation (total drug deposited in the capsule, inhaler, 
mouthpiece, throat, pre-separator and stages). The fine particle fraction 
(FPF %) of each dose was the ratio of the drug mass depositing on stages 
2 to MOC over the recovered dose. The fine particle dose (FPD) was 
calculated as the ratio of mass deposited on stage 2 to MOC, to the 
number of doses (n=3). Stage 2 had a cut-off diameter of 4.46 μm. The 
mass median aerodynamic diameter (MMAD) defined as the median 
particle diameter of the formulation deposited within the NGI, and the 
geometric standard deviation (GSD) determined as the square root of the 
ratio of the particle size at 84.13th percentile to that of 15.87th percentile. 
Both MMAD and GSD were determined from the linear region in the plot of 
the cumulative mass distribution versus the logarithm of aerodynamic 
diameters. 
2.2.4. Statistical data analysis 
An analysis of variance (one-way ANOVA) with Tukey’s multiple 
comparison test was carried out to evaluate differences between the mean 
values using Prism 6 (GraphPad Software, Inc., USA). Probability values 
less than 0.05 were considered as indicative of statistically significant 
differences. 
2.2.5. Computational study of the interaction between the crystals 
of theophylline and mannitol  
In order to gain insight into the intermolecular interactions that influence 
the mechanical properties of theophylline and mannitol, the energetic and 
structural aspects of their crystals were investigated following a 
combination of approaches, namely: crystal morphology modelling, semi-
classical density sums (SCDS-Pixel) and lattice matching calculations. 
Crystal structure coordinates for theophylline form II (CSD-REFCODE 
BAPLOT01, Ebisuzaki et al., 1997) and D-mannitol form β (CSD-REFCODE 
DMANTL07, Kaminsky and Glazer, 1997) were taken from the Cambridge 
Structural Database (Allen, 2002).  
2.2.5.1 Crystal morphology modelling 
The minimisation of the energy of the crystal lattice was performed using 
the General Utility Lattice Program (GULP v.4.3) (Gale and Rohl, 2003). 
The Dreiding 2.21 force field parameters (Mayo et al., 1990) were used in 
combination with high-quality electrostatic potential derived atomic point 
charges calculated at the 6-31G**/MP2 level of theory. For the 
determination of the atomic charges the Firefly quantum chemistry 
package was used (A. Granovsky, 
http://classic.chem.msu.su/gran/gamess/index.html), which is partially 
based on the GAMESS (US) source code (Schmidt et al., 1993). Crystal 
morphologies based on Bravais-Friedel-Donnay-Harker (BFDH) theory 
(which assumes that the slowest growing faces are those with the 
greatest interplanar spacing, dhkl) were constructed in order to identify 
faces more likely to occur in the crystal. For the morphology calculations 
the GDIS program was utilized, serving as a graphical front end to the 
GULP software program (Fleming and Rohl, 2005). 
 
2.2.5.2 Semi-classical density sums (SCDS-Pixel) calculations 
 The crystal structures were analysed using the PIXEL approach developed 
by Gavezzotti (Gavezzotti, 2005). This method provides quantitative 
determination of crystal lattice energies and pairwise intermolecular 
interactions, with a breakdown of these energies into coulombic, 
polarisation, dispersion and repulsion terms. For the derivation of PIXEL 
energies, the electron density of theophylline and mannitol were 
calculated at the 6-31G**/MP2 level of theory using the Firefly quantum 
chemistry package. Finally, energy vector diagrams were constructed 
according to Shishkin et al. (2012) using the processPIXEL package and 
the results were visualised using the Mercury software program (Bond, 
2014; Macrae et al., 2008; Shishkin et al., 2012) 
 
2.2.5.3 Computational Lattice Matching Calculations 
Possible interactions between crystal faces of theophylline and mannitol 
were probed applying a computational lattice matching approach, using 
the Geometric Real-space Analysis of Crystal Epitaxy (GRACE) software 
(Mitchell et al., 2011). Cut-off distances of dc = 0.5 Å and d0 = 0.3 Å 
were selected. The value of θ was varied in the range of −90° to 90° with 
increments of 0.5°, and a search area of 400 × 400 Å and a range of 
overlayer hkl planes from −3 ≤ h, k, l ≤ +3 were employed. The epitaxy 
score, E, was calculated using the Gaussian function. The chemical 
complementarity at the geometrically matching crystal faces was 
evaluated by visual inspection of the crystal structures using the Mercury 
software program (Macrae et al., 2008). 
 
3. RESULTS AND DISCUSSION 
3.1 Preparation of microcomposite particles 
Isopropanol (IPA) was selected as the wet milling medium based on 
preliminary solubility measurements. The lower solubility of anhydrous 
theophylline in IPA (2.81 ± 0.18 mg ml-1, at 25 o C for 24h) compared to 
its aqueous solubility (7.36 mg ml-1, at 25 o C, Yalkowsky and He, 2003) 
ensures the formation of nanocrystals that will be suspended in the liquid 
medium. Also, it may limit the risk of solution-mediated phase 
transformation that can give rise to increased amounts of amorphous 
form. Moreover, anhydrous theophylline is transformed to monohydrate 
when processed in water, while such hydration transition is not expected 
to occur in IPA. 
Wet bead milling of anhydrous theophylline, in IPA, did not result in the 
production of nanosized particles, even after 6 h milling. By contrast, wet 
milling of mannitol in IPA resulted in submicron-sized particles as can be 
seen from the microcomposites obtained after spray drying of the 
suspension. The minor axis and major axis of the primary mannitol 
nanocrystals based on image analysis of SEM images and was found to be 
405.44 ± 58.72 nm and 724.24 ± 113.46 nm, respectively. Therefore, 
use of isopropanol as the wet milling medium and mannitol as co-milling 
agent were selected.  
The use of mannitol (MAN) as a co-grinding agent, enhancing the size 
reduction of drug particles and even leading to an increase in their 
bioavailability, has been reported previously (Kubo et al., 1996; Takahata 
et al., 1992). However, in these earlier studies dry grinding techniques 
were used and the authors mainly focused on bioavailability studies in 
animals rather than on the mechanism underlying size reduction of drug 
particles in the presence of mannitol.  
Mannitol is a commonly used matrix former during the solidification of 
aqueous nanosuspensions, for both oral and pulmonary drug delivery 
(Malamatari et al., 2016). It is usually incorporated prior to spray drying 
due to its high aqueous solubility, and forms a continuous matrix around 
the drug nanocrystals enhancing their redispresibility on rehydration 
(Chaubal and Popescu, 2008; Yue et al., 2013). It should be highlighted 
that in this study mannitol is not dissolved prior to spray drying but is 
added before the wet milling of anhydrous theophylline. So, both 
substances are in suspended form due to their marginal solubility in IPA. 
The total concentration of solids (THEO and MAN) in suspension was kept 
constant (5% w/v) and different THEO to MAN mass ratios (i.e. 25:75, 
50:50 and 75:25) were employed (Table 1) in order to elucidate the 
potential effect on theophylline’s particle size reduction, and also on the 
micromeritic, solid state and aerosolisation properties of the 
microcomposite particles produced.  
3.2 Characterisation of microcomposite particles 
3.2.1 Micromeritic properties  
The SEM images of starting materials are presented in Fig.1. Anhydrous 
theophylline (THEO) particles consisted of primary crystallites bound 
together to form needle–shaped particles with a D50% of 124.12 ± 18.33 
μm. Mannitol particles also exhibited an elongated morphology, with a 
D50% of 68.07 ± 1.36 μm (Table 2).  
SEM images of the microcomposites produced by wet milling and spray 
drying are given in Fig.2. Wet milling of theophylline in the absence of 
mannitol followed by spray drying resulted in particles with smaller size 
compared to the raw drug, exhibiting a D50% of 4.64 ± 0.87 μm and an 
aspect ratio of 0.41 ± 0.14, with values closer to 1 indicating a more 
spherical shape. The slight increase in the aspect ratio values of spray 
dried suspended theophylline (SD susp. THEO) compared to the raw 
material (0.33 ± 0.18) indicated the susceptibility of theophylline crystals 
to break along their short axis (Ho et al. 2012).  
Simultaneous wet milling of theophylline and mannitol in isopropanol 
followed by spray drying resulted in microcomposite particles, which 
consist of theophylline and mannitol crystals assembled together (Fig.2). 
They exhibited D50% values ranging from 3.5 to 2 μm, with size decreasing 
as mannitol content increased, and D90% values below 10 μm making 
them suitable for pulmonary drug delivery (Table 2). 
Moreover, inclusion of increasing amounts of mannitol produced particles 
with increased sphericity and porosity, demonstrated by the aspect ratio 
closer to 1 and higher specific surface area and pore volume values, 
respectively (Table 2 and 3). Thus, addition of mannitol during wet milling 
in isopropanol facilitated the size reduction of theophylline crystals and 
their assembly in microcomposites by forming porous and spherical 
agglomerates of mannitol nanocrystals in which submicron theophylline 
particles are embedded. 
3.2.2 Solid state characterisation 
The solid state of both theophylline and mannitol in the microcomposite 
formulations may change either during milling or spray drying. This was 
examined as different solid forms exhibit different physicochemical and 
mechanical properties, which may influence processability during product 
manufacturing and also drug stability, solubility, dissolution and ultimately 
therapeutic efficacy (Adeyeye et al., 1995; Raw et al., 2004). 
Mannitol is known to be highly crystalline even during milling and spray 
drying. It exists in three polymorphic forms; alpha (α), beta (β) and delta 
(δ) (Fronczek et al., 2003). The β-form is the stable form of mannitol 
however both α- and δ-forms were found to be chemically and physically 
stable for at least 5 years when stored at 25 o C and 43% relative 
humidity (Burger et al., 2000). Preparation of mannitol particles by 
different methods (e.g. freeze drying, spray drying, jet milling or 
antisolvent crystallisation) as well as process parameters during spray 
drying (i.e. outlet temperature) have been reported to influence the solid 
form of D-mannitol (Kaialy and Nokhodchi, 2013; Maas et al., 2011; Tang 
et al., 2009).  
XRPD is a fast and straightforward method for determining the basic 
information regarding the solid state of a powdered material with a limit of 
crystallinity detection in amorphous drug compositions around 5-10% 
(Stephenson et al., 2001). According to the XRPD patterns of the starting 
materials (Fig. 3), the diffraction peaks of anhydrous theophylline are 
characteristic of the form II (2 theta: 7.2 o, 12.6 o, 14.5 o) while for 
mannitol they are characteristic of the β form (2 theta: 14.7 o, 18.8 o, 
23.6 o, 29.5 o). Similar results regarding the solid state of Pearlitol 160C®, 
the commercial type of mannitol used in our study, were reported in other 
studies (Cares-Pacheco et al., 2015; Hulse et al., 2009).  
The XRPD pattern of the spray-dried microcomposites of THEO wet milled 
alone (SD susp. THEO) exhibited the same characteristic peaks as the 
starting material, indicating that both processes (i.e. wet milling coupled 
by spray drying) did not alter the polymorphic form of anhydrous 
theophylline (Fig. 3). Similarly, the spray-dried microcomposite of 
mannitol wet milled alone (SD susp. MAN) was in the same form as the 
raw material (form β) (Fig. 3). 
For the microcomposites containing both THEO and MAN wet milled 
together in different mass ratios, the diffraction patterns shown in Fig. 3, 
were essentially a summation of the patterns of the starting materials. In 
all cases, reduction in the intensities and broadening of the peaks, 
compared to the patterns of the starting materials, can be attributed to 
the smaller size of the primary crystals in the microcomposite 
formulations and strain caused by the milling process (Hecq et al., 2005).  
DSC was used to assess the thermal behaviour of the starting materials 
and the microcomposite formulations (Fig. 4). The DSC curve of the raw 
THEO showed an endothermic melting peak at 273 o C. The same thermal 
transition was observed for the SD susp. THEO formulation. The DSC of 
mannitol starting material (Pearlitol 160C®) and the SD susp. MAN showed 
one sharp endothermic peak at 167 o C that relates to the melting of 
mannitol crystals. Regarding the DSC curves of the microcomposite 
particles containing both THEO and MAN, instead of the expected two 
endothermic events corresponding to the melting of the two components, 
a change in the thermal behaviour of theophylline was observed in the 
presence of mannitol. More specifically, after the melting of mannitol at 
around 165 o C, theophylline appeared to dissolve completely in the 
melted mannitol when a drug load of up to 50%w/w was used, and 
partially at higher drug loads leading to the broadening of the melting 
peak of theophylline and a shift towards lower temperature (around 255 o 
C) compared to the raw THEO material. However, as the FT-IR spectra of 
the physical mixtures and spray-dried suspensions of THEO and MAN 
presented the same bands as the raw materials (Fig. 5), it can be 
assumed that the interaction between theophylline and mannitol is limited 
to temperatures above the melting point of mannitol (166 ± 2oC). Similar 
results have been reported on the interaction of mannitol with other drugs 
(e.g. carbamazepine and promethazine hydrochloride) indicating that DSC 
should not be used alone to detect any inherent incompatibility between 
substances but it has to be combined with other non-thermal techniques, 
such as XRPD and FT-IR (Flicker et al., 2011; Joshi et al., 2002; Thumma 
and Repka, 2009). 
Overall, the XRPD data suggest that the engineered microcomposite 
formulations retain their crystallinity during wet bead milling followed by 
spray drying. The preservation of the crystalline state is advantageous, 
ensuring the long-term physical stability of the formulations during 
storage. At this point, it should be highlighted, that dry milling techniques 
(e.g. air jet milling and ball milling) can induce crystal defects and even 
cause surface amorphisation of the particles (Ward and Schultz, 1995). 
These phenomena seem to be avoided during wet bead milling, as the 
liquid medium ensures rapid recrystallisation of potentially formed 
amorphous regions (Kayaert and Van den Mooter, 2012). Another 
suggested mechanism is that the liquid media allows fast cooling during 
particle breakage, which can minimise formation of local hot spots on 
particle surfaces and thus reduce the extent of surface amorphisation 
(Monteiro et al., 2012). 
 
3.2.3 Drug loading 
The results of THEO content in microcomposites are given in Table 1. The 
assayed THEO content was close to the nominal, indicating no significant 
loss or powder segregation during the production processes. The small 
deviation of the assayed THEO amount compared to the theoretical value 
may be attributed to the suspension collection method employed at the 
end of the milling process. Separation by pipetting cannot achieve total 
suspension recovery with small amounts remaining among the beads. In 
industrial settings this is unlikely to be an issue as mills with separate 
holding and receiving tanks equipped with paddle mixers are used 
(Monteiro et al., 2012). In this way, enhanced suspension homogeneity 
and recovery are ensured leading to the production of formulations with 
consistent drug loading.  
 
 
3.2.4 In vitro aerosol performance 
The drug deposition profiles of the formulations produced are shown in 
Fig. 6, while parameters of their aerosol performance are given in Table 4. 
The SD susp. THEO exhibited a significantly lower emitted fraction (EF%) 
of 65.6 ± 0.8 compared to the formulations containing mannitol (p<0.05), 
which may be attributed to the needle-shaped morphology. Elongated 
particles, despite their ability to travel further in the lung airway, were 
found to have poor dispersion from inhaler when administered as dry 
powders for inhalation as they are subject to strong attractive forces when 
in contact along their axis (Crowder et al., 2002). For the formulations 
containing mannitol reduced capsule and device retention was observed, 
leading to EF% around 80% for all the various theophylline to mannitol 
(THEO:MAN) ratios examined in this study (Table 4). This may be 
attributed to their more spherical size that allows them to leave the 
capsule and device by the additional mechanism of rolling.  
 
Wet milling of theophylline in the presence of mannitol followed by spray 
drying resulted in particles with enhanced aerosol performance as 
demonstrated by the higher fine particle fraction (FPF%) and fine particle 
doses (FPD) achieved compared to the SD susp. THEO. More specifically, 
the SD susp. THEO achieved a FPF of 26.1 ± 7.1 % and a mass median 
aerodynamic diameter (MMAD) of 4.5 ± 1.1 μm while incorporation of 
mannitol resulted in  approximately 2- fold increase in FPF% (p<0.01), 
depending on the drug to mannitol ratio, and in MMADs close to 3 μm for 
the respective formulations (Table 4). Increasing the concentration of 
mannitol from 25% to 50% w/w or 75% w/w resulted in slightly higher 
FPF% however the increase was not found statistically significant 
(p>0.05). Moreover, increasing mannitol concentration shifted drug 
deposition from stages 2 and 3 to lower stages of the impactor (i.e. 
stages 4 to 6) (Fig. 6).  
 
It is known, that the aerodynamic diameter, which is a function of the 
geometric size and particle density, governs the behaviour of a particle in 
the airstream. Thus, the improved aerosolisation efficiency of the 
formulations containing mannitol may be attributed to their smaller 
particle size and increased porosity compared to SD susp. THEO (Table 2 
and 3). 
 
Previously, when mannitol was added as a matrix former in aqueous 
nanosuspensions prior to the spray-drying step it was found to have no 
significant influence on the surface roughness and aerosol performance of 
the nano-matrix powders produced (Yamasaki et al., 2011). This result, 
which at first sight seems contradictory to our conclusions, can be 
explained by the fact that mannitol was dissolved in the aqueous drug 
nanosuspensions and during spray drying it formed a continuous matrix 
around the drug nanocrystals. In our case, mannitol nanocrystals were 
suspended in isopropanol prior to the spray-drying step, and after solvent 
evaporation they formed porous agglomerates wherein theophylline 
particles were embedded.  
 
3.3 Computational study of the interactions between theophylline 
and mannitol 
Results of PIXEL calculations for theophylline form II and mannitol form β 
are given in Table 5. Results on the mechanical properties of the crystals, 
calculated by molecular mechanics force field methods are presented in 
Table 6. Regarding the energy decomposition results for theophylline 
(Table 5), only the repulsive component is destabilising with all the other 
energy terms to contribute to the crystal lattice stabilisation. More 
specifically, the dispersion and coulombic components have almost equal 
contributions regarding the stabilisation. These results are in agreement 
with previously published data (Dunitz and Gavezzotti, 2005). In the case 
of mannitol, the coulombic component is by far the most important 
stabilising interaction, reflecting the significance of the hydrogen bonds in 
the stabilisation of the crystal structure. 
The crystal morphologies of theophylline and mannitol, determined 
according to the BFDH theory and energy vector diagrams are shown in 
Fig. 7. From Fig. 7c, it is seen that, as already described by Dunitz and 
Gavezzotti (2005), theophylline forms stacked dimers, but those dimmers 
do not form layers in the crystal structure, and there are strings of N-H···N 
hydrogen bonds between non-coplanar molecules. The direction of 
(stabilising) coulombic and polarisation, as well as the (destabilising) 
exchange repulsion interaction forces, coincides with the hydrogen bonding 
motif. On the other hand, the (stabilising) dispersion interaction forces 
extend mainly between adjacent coplanar purine rings, normal to the 
plane defined by the N-H···N hydrogen bond strings. 
The spatial arrangement of the interaction forces in the lattice of 
theophylline defines the (200) plane as the most probable slip direction 
since no significant interaction forces act along or intersect this plane. 
However, as it becomes evident from the calculated crystal morphology in 
order to cause shearing of the crystal along the (200) plane, a force has 
to act on the much smaller (110) or (201) faces (Fig.7a). The small 
relative surface area of these crystal faces, which is expected to get 
gradually smaller as milling proceeds, together with the rather high 
stiffness of its crystal structure (relatively high values of Young’s modulus, 
Table 6) is probably the cause of the difficulty to break theophylline 
crystals by milling. 
Mannitol exhibits a needle-like habit, with elongation along the a 
crystallographic axis, which is adequately represented by the BFDH 
morphology model, Fig. 7b. As demonstrated by the energy vector 
diagram of mannitol (Fig. 7d), intermolecular interaction forces extend 
parallel to the c crystallographic axis, clearly defining a slip direction along 
the (020) plane, in agreement with literature data (Al-Khattawi et al., 
2015; Ho et al., 2012). Moreover it has been reported that mannitol 
crystals also fracture along the (011) plane (Ho et al. 2012). According to 
the energy vector diagram of mannitol, strong stabilising forces act along 
this plane, therefore fracture should not be very likely. However, when the 
elongated habit of the crystals is taken into account, it becomes evident 
that mechanical forces normal to the elongation axis eventually prevail 
and cause fracture. 
Regarding the mechanism by which mannitol facilitates the size reduction 
of theophylline, this may be attributed to the interaction between certain 
crystal faces of the two substances, leading to subsequent adsorption-
induced reduction of strength of a solid (AIRS); a phenomenon of 
physicochemical mechanics also known as Rehbinder effect (Rehbinder 
and Shchukin, 1972). According to Rehbinder, adsorption of additives on 
the surface of the particles can make crack propagation easier by way of 
reduction in surface energy (Andrade et al., 1950).  
In order to investigate potential interactions between crystal faces of 
theophylline and mannitol, geometric lattice matching calculations were 
employed. It should be noted that geometric lattice matching calculations 
are developed to study epitaxial growth (i.e. growth of one crystal 
(overlayer) on the surface of another crystal (the substrate), on which the 
growth of the overlayer is oriented by the lattice structure of the 
substrate) (Datta and Grant, 2004). However, as the epitaxy score relates 
to the density and precision of lattice coincidence within a predefined 
search area and the higher its value, the larger the area a substrate and 
an overlayer can maintain a favourable low energy interaction, we 
extended the use of these calculations in our case (Lee et al., 2010).  
No significant geometric matching was found between the (200) plane of 
theophylline and (020) plane of mannitol. On the contrary, a high E value, 
the epitaxy score, indicates good matching between the (200) plane of 
theophylline and the (011) plane of mannitol. The value of the best 
matching theta, the angle between the (200) plane of theophylline and 
the (011) plane of mannitol is -79.5 o with an E value of 5.4895 (Fig. 8a). 
A one-dimension Moiré plot shows a high degree of superimposed patterns 
for theophylline’s (200) and mannitol’s (011) crystal plane, which is 
typical of registry between the two crystal lattices (Fig. 8b).  
The geometric matching of the lattice planes provides an indication of 
favourable interactions that could also lead to attachment of one crystal 
on the other, initiating processes involved in the adsorption-induced 
reduction of strength of theophylline particles. These results, together 
with the different physicomechanical properties of the compounds may 
shed light on the mechanisms behind the enhancement of theophylline’s 
particle size reduction by mannitol during wet milling.  
4. CONCLUSIONS 
Inhalable-sized particles of theophylline with various amounts of mannitol 
were successfully prepared by wet milling in isopropanol followed by spray 
drying. The addition of mannitol as a co-milling agent facilitated the size 
reduction of theophylline needle-like crystals and resulted in 
microcomposite particles which consisted of theophylline and mannitol 
submicron crystals assembled together. The microcomposites were found 
to be in the same crystalline state as the starting material(s). Increasing 
the proportion of mannitol was found to result in the production of 
smaller, more spherical and porous particles with enhanced aerosol 
performance. Crystal morphology modelling and geometric lattice 
calculations were useful tools providing an insight into the intermolecular 
interactions that may influence the mechanical properties of theophylline 
and mannitol and the role of the latter as a co-milling agent. Overall, wet 
milling of drugs in an organic solvent in the presence of mannitol, followed 
by spray drying, can be used a formulation approach for the production of 
respirable particles of water-soluble drugs or drugs that are prone to 
crystal transformation in an aqueous environment (i.e. formation of 
hydrates). Preservation of the solid phase makes this approach preferable 
to micronisation by dry milling techniques, which is associated with 
limitations, such as drug amorphisation and performance variability.  
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Table 3. Nominal composition and assayed theophylline content (% w/w) of microcomposite particles together with the 
calculated drug loading efficiency (%) (mean ± SD, n=3). 
Formulation 
Content (% w/w) 
Drug loading 
efficiency (%) 
Nominal  Assayed 
THEO Mannitol  THEO 
SD susp. THEO 100 -  n/a n/a 
SD susp. THEO:MAN 75:25 75 25  76.2 ± 0.1 101.6 ± 0.1 
SD susp. THEO:MAN 50:50 50 50  53.3 ± 0.1 106.7 ± 0.1 
SD susp. THEO:MAN 25:75 25 75  28.7 ± 0.2 114.1 ± 1.0 
SD susp. MAN - 100  n/a n/a 
 
 
 
Table 2. Particle size distribution data and aspect ratio values of the starting materials and microcomposite formulations 
containing different theophylline to mannitol ratios (mean ± SD, n=3). 
Formulation 
Size distribution: d10, d50, d90 
 
(4 bar, 50 mm s-1) 
Image 
analysis 
 
D10%(μm) D50% (μm) D90% (μm) Aspect ratio 
THEO 29.90 ± 1.76 124.12 ± 18.33 352.27 ± 54.75 0.33 ± 0.18 
Mannitol 12.23 ± 0.34 68.07 ± 1.36 208.13 ± 3.96 0.58 ± 0.21 
SD susp. THEO 1.17 ± 0.31 4.64 ± 0.87 13.80 ± 4.60 0.41 ± 0.14 
SD susp. THEO:MAN 75:25 0.97 ± 0.06 3.52 ± 0.68 9.72 ± 2.40 0.55 ± 0.15 
SD susp. THEO:MAN 50:50 0.82 ± 0.05 2.95 ± 0.64 7.91 ± 1.95 0.68 ± 0.19 
SD susp. THEO:MAN 25:75 0.61 ± 0.08 2.18 ± 0.30 5.11 ± 1.22 0.71 ± 0.12 
SD susp. MAN 0.58 ± 0.03 2.86 ± 0.12 6.39 ± 0.50 0.85 ± 0.09 
 
Table 3. Specific surface area, total pore volume and average pore radius of the starting materials and microcomposite 
formulations containing different theophylline to mannitol ratios (n=3)*. 
 
 
Formulation 
 
 
BET 
Surface area 
(m2 g-1) 
 
Total 
Pore Volume 
(cc g-1) x103 
 
Average 
Pore Radius 
(Å) 
THEO 0.80  2.31 24.11 
Mannitol 0.36  1.26 11.39 
SD susp. THEO 5.23  8.63 21.82 
SD susp. THEO:MAN 75:25 8.97  14.71 32.79 
SD susp. THEO:MAN 50:50 9.64  20.14 41.77 
SD susp. THEO:MAN 25:75 11.57  25.99 44.93 
SD susp. MAN 19.73  39.13 39.67 
* Relative standard deviation <4% 
 
Table 4. Aerodynamic parameters of microcomposite formulations containing different theophylline to mannitol ratios 
delivered using the Cyclohaler® at 60L min-1 (mean ± SD, n=3).  
Formulation 
Emitted fraction 
(EF %) 
Fine particle 
fraction 
(FPF %) 
Fine particle 
dose 
(FPD, mg) 
 
Mass median 
aerodynamic 
diameter 
(MMAD, μm) 
 
Geometric 
Standard 
Deviation 
(GSD) 
SD susp. THEO 65.6 ± 0.8 26.1 ± 7.1 2.6 ± 0.6 4.5 ± 1.1 1.7 ± 0.1 
SD susp. THEO:MAN 75:25 84.0± 0.4 47.9 ± 2.3 4.8 ± 0.2 3.1 ± 0.2 1.6 ± 0.1 
SD susp. THEO:MAN 50:50 78.9 ± 12.9 56.1 ± 0.8 5.6 ± 0.1 3.2 ± 0.3 1.6 ± 0.0 
SD susp. THEO:MAN 25:75 84.1 ± 4.6 56.8 ± 8.7 5.7 ± 0.9 2.9 ± 0.1 1.7 ± 0.1 
Table 5. Lattice energy (kJ/mol) decomposition according to the 
PIXEL scheme, for theophylline form II and mannitol form β. ECOUL: 
coulombic; EPOL: polarisation; EDISP: dispersion; EREP: repulsion and 
ETOTAL: total intermolecular interaction energy. 
Substance ECOUL EPOL EDISP EREP ETOTAL ΔΗSUB 
THEO -95.5 -47.5 -
109.0 
123.2 -
128.9 
135.0* 
Mannitol -
312.7 
-139.7 -
132.2 
356.7 -
227.8 
202.0* 
*Sublimation enthalpies (ΔΗSUB) were taken from 
http://webbook.nist.gov/chemistry 
 
 
Table 6. Calculated mechanical properties of theophylline form II 
and D-mannitol form β. 
 THEO Mannitol 
Bulk modulus (GPa) 14.81 10.85 
Shear modulus (GPa) 4.59 4.15 
Compressibility (GPa-1) 0.0675 0.0922 
Young modulus (GPa) 
Ex 18.6 75.6 
Ey 15.5 15.1 
Ez 22.0 20.5 
 
  
FIGURES 
Figure 1. SEM images of starting materials. 
Figure 2. SEM of microcomposite formulations containing 
theophylline and mannitol wet milled alone and in 
different mass ratios.  
 
Figure 3. XRPD patterns of starting materials and microcomposite 
formulations containing different theophylline to 
mannitol ratios.  
 
Figure 4. DSC thermograms of starting materials and 
microcomposite formulations containing different 
theophylline to mannitol ratios. 
 
Figure 5. FT-IR spectra of starting materials, physical mixture 
(PM) of theophylline and mannitol (mass ratio 50:50) 
and SD susp. THEO:MAN 50:50.  
Figure 6. Drug deposition profiles of microcomposites containing 
different theophylline to mannitol ratios using the 
Cyclohaler® at 60L min-1 (mean + SD, n=3). St.1-St.7 
denote stages 1-7 of the NGI, the aerodynamic cut-off 
diameter of each stage is given in parenthesis.  
 
Figure 7. Chemical structures and crystal morphologies of (a) 
theophylline anhydrous form II and (b) D-mannitol β 
form. Crystal morphologies are calculated according to 
the BFDH theory showing the orientation of the unit cell 
in the bulk crystal. Energy vector diagrams of (c) 
theophylline form II showing the direction of coulombic 
and polarisation (pink) and dispersion (yellow) 
interactions, and of (d) D-mannitol β form, showing the 
direction of combined stabilising (pink) and destabilising 
repulsive (green) interactions. Red surfaces indicate the 
most probable slip planes. 
 
Figure 8. (a) Epitaxy score vs rotation angle and (b) Moiré 
patterns for the geometric matching of theophylline’s 
(100) on mannitol’s (011) crystal plane.
 
 
Figure 1. SEM images of starting materials. 
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Figure 2. SEM of microcomposite formulations containing theophylline and mannitol wet milled alone and in different mass 
ratios. 
SD susp. THEO 
SD susp. THEO:MAN 75:25 SD susp. THEO:MAN 50:50 
SD susp. MAN 
SD susp. THEO:MAN 25:75 
4 µm 4 µm 
4 µm 4 µm 4 µm 
 
 
Figure 3. XRPD patterns of starting materials and microcomposite formulations containing different theophylline to mannitol 
ratios. 
 
 
 
 
Figure 4. DSC thermograms of starting materials and microcomposite formulations containing different theophylline to 
mannitol ratios. 
  
 
Figure 5. FT-IR spectra of starting materials, physical mixture 
(PM) of theophylline and mannitol (mass ratio 50:50) and SD susp. 
THEO:MAN 50:50. 
 
 
Figure 6. Drug deposition profiles of microcomposites containing different theophylline to mannitol ratios using the 
Cyclohaler® at 60L min-1 (mean + SD, n=3). St.1-St.7 denote stages 1-7 of the NGI, the aerodynamic cut-off diameter of 
each stage is given in parenthesis. 
 
 
Figure 7. Chemical structures and crystal morphologies of (a) 
theophylline anhydrous form II and (b) D-mannitol β form. Crystal 
morphologies are calculated according to the BFDH theory showing 
the orientation of the unit cell in the bulk crystal. Energy vector 
diagrams of (c) theophylline form II showing the direction of 
coulombic and polarisation (pink) and dispersion (yellow) 
interactions, and of (d) D-mannitol β form, showing the direction of 
combined stabilising (pink) and destabilising repulsive (green) 
interactions. Red surfaces indicate the most probable slip planes.
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Figure 8. (a) Epitaxy score vs rotation angle and (b) Moiré patterns for the geometric matching of theophylline’s (100) on 
mannitol’s (011) crystal plane. 
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